Severe Alzheimer's patient shows improved cognition and speech after psilocybin dose
By
Mattha Busby
Summary
A case report describes a woman with severe Alzheimer's disease who, after receiving a large dose of psilocybin, began initiating conversations after years of only speaking in monosyllables. She also regained bladder control and experienced improved mobility in the weeks following treatment. The case adds to growing evidence that psychedelics may alter cognition and brain function, though further research is needed.
Source
Twitter / XSevere Alzheimer's patient shows improved cognition and speech after psilocybin dosenewscientist.comKey quotes
· 3 pulledHer facial expressions became much more animated; she made prolonged eye contact
A woman with severe Alzheimer's disease who spent years communicating in monosyllables started initiating conversations after receiving a large dose of psilocybin
The case adds to evidence that psychedelics can acutely alter cognition and brain function
You might also wanna read
Transient functional improvements in advanced Alzheimer's disease following high-dose psilocybin: a case report
This case report describes an 80-year-old Japanese-American woman with advanced Alzheimer's disease (10-year history, 5 years of severe hypo
frontiersin.org·8d ago
Psilocybin Delays Cellular Aging and Extends Lifespan in Preclinical Study
Psilocybin, the active compound in psychedelic mushrooms, significantly delayed cellular aging and extended lifespan in a preclinical study
neurosciencenews.com·11mo agoPsilocybin's Anti-Aging Effects Revealed in New Emory University Study
A new study suggests that psilocybin, the active ingredient in psychedelic mushrooms, may have anti-aging properties by extending cellular l
Psilocybin's Impact on Depression and Anxiety in Cancer Patients: Study Findings
A randomized double-blind trial studied the effects of psilocybin on 51 cancer patients with symptoms of depression and anxiety. Results sho
pmc.ncbi.nlm.nih.gov·11mo ago
Synthetic Psilocybin Shows Strong Results in Treatment-Resistant Depression Trials
Compass Pathways, a British biotech company, announced strong results from two late-stage trials showing that a synthetic form of psilocybin
economist.com·4mo ago
Monash University study finds copper-delivering drug Cu(ATSM) reduces Alzheimer's proteins and improves memory in lab tests
Monash University researchers have discovered that a copper-delivering drug called Cu(ATSM) significantly reduces toxic Alzheimer's proteins
monash.edu·8d agoComments
Sign in to join the conversation.
No comments yet. Be the first.